Diagnosis, Assessment, and Therapeutic Strategy for Colorectal Mixed Adenoneuroendocrine Carcinoma

被引：44

作者：

Tanaka, Toshiaki ^{[1
]}

Kaneko, Manabu ^{[1
]}

Nozawa, Hiroaki ^{[1
]}

Emoto, Shigenobu ^{[1
]}

Murono, Koji ^{[1
]}

Otani, Kensuke ^{[1
]}

Sasaki, Kazuhito ^{[1
]}

Nishikawa, Takeshi ^{[1
]}

Kiyomatsu, Tomomichi ^{[1
]}

Hata, Keisuke ^{[1
]}

Morikawa, Teppei ^{[2
]}

Kawai, Kazushige ^{[1
]}

Watanabe, Toshiaki ^{[1
]}

机构：

[1] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan

[2] Univ Tokyo, Dept Pathol, Tokyo, Japan

来源：

NEUROENDOCRINOLOGY | 2017年 / 105卷 / 04期

关键词：

Mixed adenoneuroendocrine carcinoma; Colon Rectum; LARGE-CELL NEUROENDOCRINE; PHASE-III TRIAL; 1ST-LINE TREATMENT; PREOPERATIVE RADIOTHERAPY; SURGICAL-TREATMENT; LIVER METASTASES; COLON; TUMORS; CANCER; CT;

D O I：

10.1159/000478743

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Colorectal mixed adenoneuroendocrine carcinoma (MANEC), which acts like an aggressive tumor, is a rare clinical manifestation on which only a limited amount of literature exists. Surgical resection by regional lymphadenectomy is considered as the only curative treatment for colorectal MANEC, and adjuvant chemotherapy or radiotherapy is recommended because of its high recurrence rate. Colorectal MANEC is frequently diagnosed at an advanced stage, when it is unresectable, and chemotherapy plays a central role in its treatment. Pathological confirmation of the target lesion component is critical for egimen selection. If the lesion comprises an adenocarcinomatous component, a regimen for colorectal adenocarcinoma should be administered. For lesions comprising mainly a neuroendocrine carcinomatous component, cisplatin combined with etoposide or irinotecan has proven to be clinically appropriate. Everolimus, a mechanistic target of rapamycin pathway inhibitor, also improves survival. Sunitinib malate, another molecular targetng agent, is effective for treating neuroendocrine carcinoma; however, the evidence on its effectiveness for treating gastrointestinal neuroendocrine carcinoma is insufficient. (C) 2017 S. Karger AG, Basel

引用

页码：426 / 434

页数：9

共 72 条

[1]

[Anonymous], 2015, J NATL COMPR CANC NE

[2] The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs) Well-Differentiated NETs of the Distal Colon and Rectum [J].